Eckert & Ziegler Strahlen- und Medizintechnik AG / Quarter Results
05.05.2009
Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 05.05.2009. In the first quarter 2009 the Berlin based Eckert &
Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist
for isotope technology in medicine, science and industry, in the first
quarter 2009 set new records with sales of EUR 24 million and Group profits
of EUR 2.2 million, thus far exceeding the existing operative records.
Compared with last year's period, sales increased by EUR 10 million, or
71%. Compared with the first quarter of 2008, the profit after tax and
minority interests actually increased by a factor of 2.5 when the special
effect resulting from the IBt consolidation is excluded. The operative cash
flow achieved EUR 3.4 million and also set a new record. Earnings per share
amount to EUR 0.61.
In the Nuclear Imaging and Industry segment, sales more than doubled from
EUR 5.9 million to EUR 12.6 million. This resulted from the combined
effects of the inclusion of Nuclitec sales, increased sales in robust oil
well logging sources, and a USD exchange rate improvement of 10%. Despite
the loss of sales in Italy, the Radiopharmaceuticals segment grew by 56%.
The two main product categories, Modular-Lab and contrast media for
positron emission tomography (PET), continued their growth trend from the
previous quarters. Added to this were Nuclitec's initial Auriga sales.
Sales in the Therapy segment rose by 30%. The driving forces here with more
than 20% were implants for treating prostate cancer, and tumor radiation
equipment, for which sales doubled from the previous year.
As in the previous periods, the main source of earnings was the Nuclear
Imaging and Industry segment, which contributed EUR 1.6 million to the
profit after tax. Due to economies of scale, the increase in sales led to
over-proportional increases in the operating profit/loss and in the profit
before and after tax, so that the segment's contribution to the Group's
profit almost tripled. These results also show that Nuclitec fits into the
cost structure very well and also adds to profits. In the
Radiopharmaceuticals segment, the earnings position continued to improve.
It now posted a clear profit. Gains from the deconsolidation of the Italian
stake further increased profits. For the first time since the inclusion of
IBt, the Therapy segment was able to show a clear profit. Restructuring was
completed successfully, and the expanded business is profitable.
For the current year, the company expects further growth, in particular
sales growth, to roughly EUR 100 million.
Eckert & Ziegler AG, which in 2008 achieved sales of EUR 72 million with
approx. 410 employees, is one of the world's largest providers of isotope
component technology for radiation therapy and nuclear medicine.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail: karolin.riehle@ezag.de,
www.ezag.de
DGAP 05.05.2009
---------------------------------------------------------------------------
Language: English
Issuer: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Ägypten
Phone: 49 30 941084138
Fax: 49 30 941084112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Eckert & Ziegler: New Hights in Revenues and Profits in Q 1 2009
| Source: EQS Group AG